Johnson & Johnson Price to Free Cash Flow Ratio 2010-2024 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-12-20 |
144.47 |
|
16.62 |
| 2024-09-30 |
160.77 |
$8.69 |
18.49 |
| 2024-06-30 |
143.90 |
$8.48 |
16.96 |
| 2024-03-31 |
154.48 |
$7.59 |
20.35 |
| 2023-12-31 |
151.91 |
$7.27 |
20.90 |
| 2023-09-30 |
149.76 |
$6.28 |
23.85 |
| 2023-06-30 |
158.02 |
$5.63 |
28.09 |
| 2023-03-31 |
146.87 |
$6.23 |
23.57 |
| 2022-12-31 |
166.21 |
$6.65 |
24.98 |
| 2022-09-30 |
152.72 |
$6.80 |
22.47 |
| 2022-06-30 |
164.84 |
$7.60 |
21.68 |
| 2022-03-31 |
163.55 |
$1.34 |
122.16 |
| 2021-12-31 |
156.85 |
$2.68 |
58.44 |
| 2021-09-30 |
147.10 |
$3.92 |
37.56 |
| 2021-06-30 |
149.16 |
$2.17 |
68.69 |
| 2020-12-31 |
140.74 |
$7.67 |
18.34 |
| 2020-09-30 |
132.21 |
$6.91 |
19.13 |
| 2020-06-30 |
124.06 |
$6.65 |
18.66 |
| 2020-03-31 |
114.87 |
$8.50 |
13.51 |
| 2019-12-31 |
126.96 |
$8.64 |
14.70 |
| 2019-09-30 |
111.83 |
$9.35 |
11.96 |
| 2019-06-30 |
120.39 |
$8.74 |
13.77 |
| 2019-03-31 |
120.01 |
$8.04 |
14.92 |
| 2018-12-31 |
110.06 |
$7.97 |
13.82 |
| 2018-09-30 |
117.09 |
$7.48 |
15.66 |
| 2018-06-30 |
102.15 |
$7.70 |
13.27 |
| 2018-03-31 |
107.09 |
$7.36 |
14.54 |
| 2017-12-31 |
116.02 |
$7.14 |
16.24 |
| 2017-09-30 |
107.31 |
$7.11 |
15.09 |
| 2017-06-30 |
108.49 |
$6.62 |
16.38 |
| 2017-03-31 |
101.48 |
$6.33 |
16.03 |
| 2016-12-31 |
93.26 |
$6.03 |
15.47 |
| 2016-09-30 |
94.97 |
$9.36 |
10.15 |
| 2016-06-30 |
96.87 |
$9.12 |
10.62 |
| 2016-03-31 |
85.80 |
$9.58 |
8.95 |
| 2015-12-31 |
80.87 |
$11.08 |
7.30 |
| 2021-03-31 |
147.89 |
$6.49 |
22.80 |
| 2015-09-30 |
72.96 |
$6.13 |
11.91 |
| 2015-06-30 |
75.58 |
$6.80 |
11.11 |
| 2015-03-31 |
77.45 |
$6.56 |
11.81 |
| 2014-12-31 |
79.94 |
$6.85 |
11.67 |
| 2014-09-30 |
80.96 |
$6.76 |
11.99 |
| 2014-06-30 |
78.93 |
$5.83 |
13.55 |
| 2014-03-31 |
73.60 |
$5.49 |
13.40 |
| 2013-12-31 |
68.13 |
$4.96 |
13.73 |
| 2013-09-30 |
64.04 |
$4.94 |
12.98 |
| 2013-06-30 |
62.96 |
$4.71 |
13.36 |
| 2013-03-31 |
59.34 |
$4.64 |
12.79 |
| 2012-12-31 |
50.61 |
$4.97 |
10.19 |
| 2012-09-30 |
49.32 |
$5.02 |
9.83 |
| 2012-06-30 |
47.92 |
$5.05 |
9.49 |
| 2012-03-31 |
46.34 |
$4.83 |
9.60 |
| 2011-12-31 |
45.67 |
$4.59 |
9.94 |
| 2011-09-30 |
43.94 |
$4.62 |
9.50 |
| 2011-06-30 |
45.49 |
$4.71 |
9.66 |
| 2011-03-31 |
40.17 |
$4.72 |
8.52 |
| 2010-12-31 |
41.56 |
$5.21 |
7.98 |
| 2010-09-30 |
41.27 |
$5.76 |
7.16 |
| 2010-06-30 |
38.98 |
$5.69 |
6.85 |
| 2010-03-31 |
42.64 |
$5.50 |
7.75 |
| 2009-12-31 |
41.80 |
$5.15 |
8.12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$345.687B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
